Afatinib is an investigational orally administered irreversible inhibitor of both the epidermal growth factor receptor (EGFR) and human epidermal receptor 2 (HER2) tyrosine kinases. Boehringer Ingelheim said that
Healthpoint will ship commercial lots of Collagenase Santyl Ointment produced at DPT’s Lakewood facility to its North American customers, beginning this month. DPT’s Sterile & Specialty Products center
The product candidates cover a range of therapeutic areas, including pain, obesity and parkinson’s disease, using Angiochem’s technology to enable drugs to penetrate the CNS, including biologics (peptides
Elder Biomedia is a distributor and manufacturer of oral drugs in the Bulgarian pharma market. Elder Pharmaceuticals has recently increased its stake in Elder Biomedia from 61% to
Figueroa will replace James Shelton, who has served as Omnicare’s Interim president and CEO since August 2010. Most recently, Figueroa served as president of the US Pharmaceutical Group
Access Pharma anticipates completion and delivery of its CobOral insulin formulation to the pharmaceutical company by the end of the month. Access Pharma has recently signed an agreement
Astellas will purchase approximately 1.43 million unregistered shares of Cytori common stock at $7 per share for net proceeds to Cytori of $10m. As part of the agreement,
The report, titled ‘Targeting Emerging Delivery Technologies across the Value Chain: From Chemicals and Materials Suppliers to End-Products and Applications,’ applies the Lux Innovation Grid framework to evaluate
Glycofect is designed to be particularly effective in primary cells of therapeutic interest and is being used by government, university and corporate laboratories around the world for advanced
The designation follows the grant of orphan drug designation by the FDA for QLT091001 for the treatment of Leber Congenital Amaurosis (LCA). QLT091001 is an orally administered synthetic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.